论文部分内容阅读
为探讨雌激素受体(ER)、孕激素受体(PR)在尿路移行细胞癌中的表达及生物学意义,对64例尿路移行细胞癌石蜡标本进行了免疫组化(SABC法)检测。结果是示:ER、PR阳性率分别为53.1％和50.0％;其中在高分化癌中ER、PR表达高于低分化癌;分级间比较有显著性差异(P<0.05);ER、PR阳性率随肿瘤分期升高而下降,但分期间比较无显著性差异(P>0.05);另外单发肿瘤、多发肿瘤及复发肿瘤之间,男女两性肿瘤之间及尿路各部位之间,ER、PR阳性表达率亦无显著性差异。结论:尿路移行细胞癌ER、PR有较高的表达率.且和分级正相关,提示ER、PR表达可能对尿路移行细胞癌有某种直接或间接的影响,并可作为肿瘤愈后判断指标之一。
To investigate the expression and biological significance of estrogen receptor (ER) and progesterone receptor (PR) in urothelial carcinoma and its clinical significance, immunohistochemistry (SABC) Detection. The results showed that the positive rates of ER and PR were 53.1% and 50.0%, respectively. The expression of ER and PR in well-differentiated carcinoma was higher than that in poorly differentiated carcinoma (P <0.05) (P> 0.05). In addition, single tumor, multiple tumor and recurrent tumor, between male and female tumors and between urinary tract, ER , PR positive expression rate no significant difference. Conclusion: There is a high expression rate of ER and PR in urothelial carcinoma, which is positively correlated with grading, suggesting that the expression of ER and PR may have some direct or indirect effects on urothelial carcinoma and can be used as the One of the indicators.